Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6504030 | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Jun, 2019
(4 years ago) | |
US6429210 | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Jun, 2019
(4 years ago) | |
US6504030 (Pediatric) | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Dec, 2019
(4 years ago) | |
US6429210 (Pediatric) | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | May 06, 2014 |
Pediatric Exclusivity(PED) | Nov 06, 2014 |
Market Authorisation Date: 17 November, 1997
Treatment: NA
Dosage: TABLET;ORAL